source
- Parabilis Medicines targets over $400 million in Nasdaq IPO to fund peptide pipelineParabilis Medicines, a peptide-focused biotech led by former Johnson & Johnson R&D head Mathai Mammen, announced plans for a Nasdaq initial public offering. The company aims to raise more than $40…
- ADC Therapeutics' Zynlonta confirmatory trial shows higher death rates, clouding full approval prospectsADC Therapeutics is pursuing full FDA approval for its antibody-drug conjugate Zynlonta in patients with relapsed or refractory diffuse large B-cell lymphoma. In the confirmatory study presented,…